Diagnostic Oncology
-
Improving Molecular Testing in Lung Cancer: What We Learned From the IASLC Global Survey
The past 10 years have seen a dramatic increase in novel therapeutic options for patients with lung cancer, with many treatments now personalized to the specific tumor characteristics of each […]
-
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens Following Neoadjuvant Therapies
Treatment guidelines recommend neoadjuvant or adjuvant therapies with surgery for patients with large primary tumors or clinical evidence of intrathoracic nodal spread.1,2 A recent joint IASLC–U.S. Food and Drug Administration […]
-
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
By Sylvie Lantuejoul, MD, PhD, and Mari Mino-Kenudson, MD Posted: April 16, 2020 Immune checkpoint inhibitors (ICI), which target the PD-1/PD-L1 axis with the aim of restoring anti-tumor immunity, are […]
-
Tumor Mutation Burden: Evolution of a Controversial Biomarker From the Pathologist’s Perspective
By Lynette M. Sholl, MD, and John W. Longshore, PhD, FACMG Posted: February 12, 2020 Dr. Lynette M. Sholl Dr. John W. Longshore The profound impact of immunotherapy in patients […]
-
PD-L1 in Cytology Specimens
By Anjali Saqi, MD, MBA; Deepali Jain, MD, FIAC; Lukas Bubendorf, MD; Keith Kerr, MB, ChB, MRCPath, FRCPath, FRCP(Ed); and Andre Moreira, MD, PhD Posted: December 11, 2019 Lung cancer […]
-
Global Survey for Pathologists on PD-L1 Testing: Moving Toward Standardization
By Mari Mino-Kenudson, MD, and Sylvie Lantuejoul, MD, PhD Posted: November 12, 2019 Determination of PD-L1 expression by immunohistochemistry (IHC) has been widely evaluated in clinical trials as a predictive […]
-
Special Session to Honor Dr. Adi Gazdar
By Ignacio Wistuba, MD, and John Minna, MD Posted: August 14, 2019 Dr. Adi Gazdar was a scientific pioneer, a groundbreaking pathologist, a loyal friend, and an inspiring mentor. Dr. Gazdar […]
-
Ki-67 in Pulmonary Neuroendocrine Tumors: Where Do We Stand?
By Anja C. Roden, MD, and Natasha Rekhtman, MD, PhD Posted: May 27, 2019 Dr. Anja C. Roden Pulmonary neuroendocrine tumors are classified according to the World Health Organization into typical […]
-
The IASLC Pathology Committee Recommendations for the Use of Diagnostic Immunohistochemistry in Lung Cancer
By Andre L. Moreira, MD Posted: April 1, 2019 Most of the progress in thoracic oncology is in the treatment of patients with NSCLC. The determination of subtypes of NSCLC, namely […]
-
Diagnostic Oncology: Reports from the IASLC Pathology Committee
By Keith M. Kerr, BSc, MB, ChB, FRCPath, FRCPE Posted: March 1, 2019 There was a time, remembered by us older pathologists, when the image of pathology was that of a […]
View ILCN Archives
Provider Resources